Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment

This publication has 26 references indexed in Scilit:

• Establishing the Cost-Effectiveness of New Pharmaceuticals under Conditions of Uncertainty—When Is There Sufficient Evidence?
  Value in Health, 2005
• Prognosis without treatment as a modifier in health economic assessments
  BMJ, 2005
• Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
  Journal of Clinical Oncology, 2005
• National Institute for Clinical Excellence and its value judgments
  BMJ, 2004
• Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor
  Journal of Clinical Oncology, 2004
• FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
  Journal of Clinical Oncology, 2004
• A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
  Journal of Clinical Oncology, 2004
• Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial
  Journal of Clinical Oncology, 2003
• Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
  The Lancet, 1998
• A Randomized Study of Low-Dose Subcutaneous lnterleukin-2 Plus Melatonin versus Supportive Care Alone in Metastatic Colorectal Cancer Patients Progressing under 5-Fluorouracil and Folates
  Oncology, 1995